MX2012002161A - El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento de cancer. - Google Patents

El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento de cancer.

Info

Publication number
MX2012002161A
MX2012002161A MX2012002161A MX2012002161A MX2012002161A MX 2012002161 A MX2012002161 A MX 2012002161A MX 2012002161 A MX2012002161 A MX 2012002161A MX 2012002161 A MX2012002161 A MX 2012002161A MX 2012002161 A MX2012002161 A MX 2012002161A
Authority
MX
Mexico
Prior art keywords
lapatinib
cancer
composition
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2012002161A
Other languages
English (en)
Other versions
MX367580B (es
Inventor
Nan Bing
Linda Perry Briley
Laura R Budde
Charles J Cox
Colin F Spraggs
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012002161(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of MX2012002161A publication Critical patent/MX2012002161A/es
Publication of MX367580B publication Critical patent/MX367580B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

Se proporcionan los métodos para tratar a un humano que padece cáncer que comprende administrar al menos una dosis de lapatinib o una sal farmacéuticamente aceptable o composición de la misma a un paciente, en donde dicho paciente no tiene uno o más polimorfismos alélicos seleccionados del grupo de HLA-DQA1*0201, HLADQB1*2O2, y HLADRBI*0701; los pacientes también pueden estar libres de genotipos en TNXB; rs12153855 y/o rs17207923.
MX2012002161A 2009-08-21 2010-08-20 El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento del cáncer. MX367580B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23594709P 2009-08-21 2009-08-21
US30756910P 2010-02-24 2010-02-24
PCT/US2010/046142 WO2011022633A2 (en) 2009-08-21 2010-08-20 Method of threating cancer

Publications (2)

Publication Number Publication Date
MX2012002161A true MX2012002161A (es) 2012-07-17
MX367580B MX367580B (es) 2019-08-27

Family

ID=43607603

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002161A MX367580B (es) 2009-08-21 2010-08-20 El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento del cáncer.

Country Status (26)

Country Link
US (3) US20120156200A1 (es)
EP (1) EP2467140B1 (es)
JP (1) JP5876827B2 (es)
KR (1) KR101781658B1 (es)
CN (1) CN102770140B (es)
AU (2) AU2010284092A1 (es)
BR (1) BR112012003653A2 (es)
CA (2) CA2771699C (es)
CY (1) CY1118486T1 (es)
DK (1) DK2467140T3 (es)
EA (1) EA027959B1 (es)
ES (1) ES2589377T3 (es)
HR (1) HRP20161110T1 (es)
HU (1) HUE029098T2 (es)
IL (1) IL218230B (es)
LT (1) LT2467140T (es)
ME (1) ME02492B (es)
MX (1) MX367580B (es)
PL (1) PL2467140T3 (es)
PT (1) PT2467140T (es)
RS (1) RS55074B1 (es)
SG (2) SG10201405039VA (es)
SI (1) SI2467140T1 (es)
SM (1) SMT201600296B (es)
WO (1) WO2011022633A2 (es)
ZA (1) ZA201201110B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916574B2 (en) 2009-09-28 2014-12-23 Qilu Pharmaceutical Co., Ltd. 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
KR20140117644A (ko) * 2012-01-31 2014-10-07 스미스클라인 비이참 (코르크) 리미티드 암을 치료하는 방법
GB201403820D0 (en) * 2014-03-04 2014-04-16 Isis Innovation Assay
CN104293958B (zh) * 2014-10-16 2016-09-21 卫生部北京医院 一种预测强直性脊柱炎易感性的试剂盒和方法
RU2761249C2 (ru) 2016-12-14 2021-12-06 Мерк Шарп энд Доум Корп. Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile
JP2025142656A (ja) * 2024-03-18 2025-10-01 学校法人昭和大学 アベマシクリブまたはその薬学的に許容可能な塩による肝障害発現リスクの検査方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5871918A (en) 1996-06-20 1999-02-16 The University Of North Carolina At Chapel Hill Electrochemical detection of nucleic acid hybridization
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
JP2000508912A (ja) 1996-04-19 2000-07-18 スペクトラ バイオメディカル，インコーポレイテッド 多型形態と複数の表現型との相関付け
JP4386967B2 (ja) 1996-07-13 2009-12-16 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
IL153111A0 (en) 2000-06-30 2003-06-24 Glaxo Group Ltd Quinazoline ditosylate salt compounds
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
US7794960B2 (en) * 2004-06-04 2010-09-14 Glaxosmithkline Llc Predictive biomarkers in cancer therapy
JP2007117085A (ja) 2005-09-28 2007-05-17 Genodive Pharma Kk 塩酸チクロピジンの副作用である肝臓障害の発生危険率の検査方法
WO2007099852A1 (ja) 2006-02-23 2007-09-07 National University Corporation Kanazawa University 固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット
WO2008070448A2 (en) * 2006-11-22 2008-06-12 Board Of Regents, The University Of Texas System Cancer-specific promoters
US20080131887A1 (en) * 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
WO2008112903A2 (en) * 2007-03-13 2008-09-18 The Children's Hospital Of Philadelphia Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes

Also Published As

Publication number Publication date
HRP20161110T1 (hr) 2016-11-04
WO2011022633A2 (en) 2011-02-24
JP2013502433A (ja) 2013-01-24
AU2014203270A1 (en) 2014-07-10
BR112012003653A2 (pt) 2016-03-22
EA201270298A1 (ru) 2012-12-28
PL2467140T3 (pl) 2017-04-28
CA3080511C (en) 2022-05-24
KR20120059564A (ko) 2012-06-08
EP2467140B1 (en) 2016-06-01
AU2010284092A1 (en) 2012-03-08
KR101781658B1 (ko) 2017-10-23
ME02492B (me) 2017-02-20
SI2467140T1 (sl) 2016-10-28
US20170065590A1 (en) 2017-03-09
CY1118486T1 (el) 2017-07-12
ZA201201110B (en) 2012-10-31
SMT201600296B (it) 2016-11-10
IL218230B (en) 2019-02-28
PT2467140T (pt) 2016-08-30
US9539257B2 (en) 2017-01-10
RS55074B1 (sr) 2016-12-30
SG10201405039VA (en) 2014-10-30
US20150231137A1 (en) 2015-08-20
ES2589377T3 (es) 2016-11-14
EP2467140A2 (en) 2012-06-27
WO2011022633A3 (en) 2012-12-27
CN102770140B (zh) 2017-06-23
CN102770140A (zh) 2012-11-07
US10004742B2 (en) 2018-06-26
MX367580B (es) 2019-08-27
HUE029098T2 (en) 2017-02-28
US20120156200A1 (en) 2012-06-21
LT2467140T (lt) 2016-09-12
DK2467140T3 (en) 2016-09-05
SG178439A1 (en) 2012-04-27
CA2771699A1 (en) 2011-02-24
AU2014203270B2 (en) 2016-06-16
CA2771699C (en) 2022-03-29
CA3080511A1 (en) 2011-02-24
JP5876827B2 (ja) 2016-03-02
EA027959B1 (ru) 2017-09-29
EP2467140A4 (en) 2013-11-06
IL218230A0 (en) 2012-04-30

Similar Documents

Publication Publication Date Title
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
BR112015004902A2 (pt) métodos e composição neutroprotetores anticolinérgicos
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
BR112018067906A2 (pt) métodos de tratamento de depressão usando antagonistas do receptor de orexina-2
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
PE20121520A1 (es) Formulacion farmaceutica que comprende ranolazina y dronedarona en el tratamiento de fibrilacion auricular
MX2012002161A (es) El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento de cancer.
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
DOP2006000057A (es) Composición farmaceútica para el tratamiento del cáncer
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
TW200616608A (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica
ATE543492T1 (de) Behandlung von lungenkrebs

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: NOVARTIS AG.*

FG Grant or registration